AKT1 and urinary bladder cancer: Gefitinib, the FDA-approved EGFR inhibitor, was reported to sensitize human bladder cancer cell lines to TRAIL therapy via inhibition of protein kinase B (Akt) and X-linked inhibitor of apoptosis protein (XIAP) cascades [26].